Welcome to our dedicated page for Baird Medical SEC filings (Ticker: BDMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures alongside AI-generated insights. Baird Medical operates in the medical devices segment of the healthcare sector and focuses on minimally invasive diagnostics and treatment, including microwave ablation technology for benign and malignant tumors.
When available, annual reports on Form 10-K and quarterly reports on Form 10-Q can provide details about Baird Medical’s business, risk factors, and discussion of operations. For a medical device company, these filings may include information on product lines such as microwave ablation systems, geographic markets, regulatory considerations, and research and development activities related to minimally invasive surgical instruments and surgical robotic systems.
Current reports on Form 8-K, when filed, can disclose significant corporate events, such as material agreements, changes related to manufacturing arrangements, or key developments in commercialization strategies. Proxy statements may address topics such as governance and executive compensation, which can be relevant for shareholders tracking BDMD stock.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important sections and explain complex regulatory language in more accessible terms. As forms such as 10-K, 10-Q, 8-K, and, when applicable, Form 4 insider transaction reports are made available through EDGAR, they are surfaced here with real-time updates and concise AI explanations to support more efficient review of Baird Medical’s regulatory history.
Baird Medical Investment Holdings Ltd director Ragan Joseph Douglas III filed an initial Form 3 reporting his holdings in the company. The filing shows direct ownership of 57,180 BDMD shares, establishing his starting equity position as a reporting insider, with no specific buy or sell transaction disclosed.
Baird Medical Investment Holdings Ltd director Hou Wei reported initial holdings of 91,545 RSU Shares (BDMD) in a Form 3 filing. These RSU shares are listed as directly owned, and the filing records Hou Wei’s beneficial ownership position without reporting any specific buy or sell transactions.
Baird Medical Investment Holdings Ltd director and 10% owner Wu Haimei has reported a direct holding of 18,195,281 Ordinary Shares of BDMD. The Form 3 entry reflects this ownership position, with no associated buy or sell transactions indicated in the data provided.
Baird Medical Investment Holdings Limited reported a change in its independent auditor. The company dismissed Kreit & Chiu CPA LLP and appointed Guangdong Prouden CPAs GP as its new independent registered public accounting firm, effective February 10, 2026, for the year ended December 31, 2025.
Kreit & Chiu’s prior reports for the year ended December 31, 2024 contained no adverse opinions or qualifications, and the company states there were no disagreements on accounting, disclosure, or audit scope. However, the company continues to have material weaknesses in internal control over financial reporting, including insufficient U.S. GAAP/SEC-experienced staff and the absence of a comprehensive U.S. GAAP accounting policy manual and documented controls. The new auditor is aware these material weaknesses are considered a reportable event.
Baird Medical Investment Holdings Limited has filed a prospectus to register up to 11,500,000 ordinary shares issuable upon exercise of public warrants at US$11.50 per share, plus up to 34,415,562 ordinary shares for resale by existing shareholders, including Betters Medical shareholders, the SPAC sponsor, Cohen, Grand Fortune Capital and its Hong Kong affiliate.
The company will not receive proceeds from resale of these 34,415,562 shares and expects limited cash from warrant exercises because its Nasdaq share price of US$1.63 on December 4, 2025 was well below the US$11.50 exercise price. The filing notes that, assuming warrant exercise and preferred share conversion, these resale shares represent about 70.9% of shares outstanding, and large sales could pressure the stock price. Baird Medical operates through PRC subsidiaries, highlights significant regulatory and capital-flow risks tied to China, and warns that HFCAA-related auditor inspection issues could eventually lead to a Nasdaq delisting, which could cause the ordinary shares’ value to decline substantially.